Genetic diversity of the 2009 pandemic influenza A(H1N1) viruses in Finland.
BACKGROUND
In Finland, the first infections caused by the 2009 pandemic influenza A(H1N1) virus were identified on May 10. During the next three months almost all infections were found from patients who had recently traveled abroad. In September 2009 the pandemic virus started to spread in the general population, leading to localized outbreaks and peak epidemic activity was reached during weeks 43-48.


RESULTS
The nucleotide sequences of the hemagglutinin (HA) and neuraminidase (NA) genes from viruses collected from 138 patients were determined. The analyzed viruses represented mild and severe infections and different geographic regions and time periods. Based on HA and NA gene sequences, the Finnish pandemic viruses clustered in four groups. Finnish epidemic viruses and A/California/07/2009 vaccine virus strain varied from 2-8 and 0-5 amino acids in HA and NA molecules, respectively, giving a respective maximal evolution speed of 1.4% and 1.1%. Most amino acid changes in HA and NA molecules accumulated on the surface of the molecule and were partly located in antigenic sites. Three severe infections were detected with a mutation at HA residue 222, in two viruses with a change D222G, and in one virus D222Y. Also viruses with change D222E were identified. All Finnish pandemic viruses were sensitive to oseltamivir having the amino acid histidine at residue 275 of the neuraminidase molecule.


CONCLUSIONS
The Finnish pandemic viruses were quite closely related to A/California/07/2009 vaccine virus. Neither in the HA nor in the NA were changes identified that may lead to the selection of a virus with increased epidemic potential or exceptionally high virulence. Continued laboratory-based surveillance of the 2009 pandemic influenza A(H1N1) is important in order to rapidly identify drug resistant viruses and/or virus variants with potential ability to cause severe forms of infection and an ability to circumvent vaccine-induced immunity.
Viral Infections Unit, Department of Vaccination and Immune Protection, National Institute for Health and Welfare THL, Helsinki, Finland. niina.ikonen@thl.fi
Niina
N
Ikonen
Minna
M
Haanpää
Esa
E
Rönkkö
Outi
O
Lyytikäinen
Markku
M
Kuusi
Petri
P
Ruutu
Hannimari
H
Kallio-Kokko
Laura
L
Mannonen
Maija
M
Lappalainen
Thedi
T
Ziegler
Ilkka
I
Julkunen
D005387:Finland / Q000453:epidemiology; D014644:Genetic Variation; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000235:genetics; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000235:genetics* / Q000302:isolation & purification; D007251:Influenza, Human / Q000453:epidemiology* / Q000821:virology; D009154:Mutation; D009439:Neuraminidase / Q000235:genetics; D010802:Phylogeny
D019267:Hemagglutinin Glycoproteins, Influenza Virus; D009439:Neuraminidase